Clin2
NCT06104839Possibly a fitRecruiting

Oral NXC-736 for moderate to severe alopecia areata

Alopecia Areata

Part of Skin clinical trials.

This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
73 people
Ages
19 years to 65 years
Study type
Interventional

Who can take part

  • You are between 19 and 65 years old.
  • You have moderate or severe alopecia areata (hair loss covering 25% to 95% of your scalp).
  • Your current hair loss started at least 6 months ago but less than 8 years ago.
  • Your hair loss has been stable (no significant regrowth) in the last 6 months.
  • You are willing to keep the same hairstyle and hair color for the study.
  • You have not used a JAK inhibitor (oral or topical) before, including in a clinical trial.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07533006Recruiting· Phase 2
Testing LY4005130 for severe hair loss (alopecia areata)

This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.

Fremont, California
NCT06012240Recruiting· Phase 3
Testing Upadacitinib for Severe Alopecia Areata

This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.

Birmingham, Alabama
NCT07311564Recruiting· Phase 2
Study of LAD603 for adults with severe alopecia areata

This trial tests a new medication called LAD603 for people with severe to very severe alopecia areata, a condition causing significant hair loss. It aims to see if the drug can help regrow hair.

Omaha, Nebraska
NCT07133308Recruiting· Phase 3
Study of deuruxolitinib for teens with severe alopecia areata

This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.

Birmingham, Alabama
NCT07205159Recruiting· Phase 1
A study of FB102 for severe alopecia areata

This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.

Saint Leonards, New South Wales (nsw)
NCT07617597Recruiting· Phase 3
Testing deuruxolitinib for severe hair loss in Japanese adults

This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.

Asahikawa

Hear when a new Alopecia Areata trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.